Silence Therapeutics plc
SLNNASDAQHealthcare● Active
$6.20
+$0.03(+0.49%)
Market Cap$292850478
P/E Ratio—
52W High$8.4
52W Low$4.19
Silence Therapeutics plc (SLN) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SLN · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.56M | $43.26M | $25.38M | $17.65M | $12.41M |
| Cost of Revenue | $0.21M | $11.81M | $10.32M | $10.97M | $7.46M |
| Gross Profit | $0.34M | $31.45M | $15.06M | $6.68M | $4.96M |
| Gross Margin %(computed) | 61.54% | 72.70% | 59.34% | 37.83% | 39.94% |
| Operating Expenses | |||||
| R&D Expenses | $67.75M | $67.88M | $44.02M | $35.50M | $30.77M |
| G&A Expenses | $22.34M | $26.88M | $20.64M | $20.94M | $20.01M |
| Total Operating Expenses | $90.10M | $94.77M | $64.66M | $56.44M | $50.77M |
| Operating Income | ($89.75M) | ($63.32M) | ($49.60M) | ($49.76M) | ($45.81M) |
| Operating Margin %(computed) | — | -146.38% | -195.48% | -281.87% | -369.02% |
| Interest Income | $3.48M | $4.47M | $1.45M | $0.23M | $0.01M |
| Interest Expense | $0.00M | $0.00M | $0.03M | $0.05M | $0.01M |
| Income Before Tax | ($88.60M) | ($44.46M) | ($50.31M) | ($40.47M) | ($45.86M) |
| Income Tax Expense | $0.01M | $0.84M | ($7.04M) | $0.56M | ($6.45M) |
| Net Income | ($88.61M) | ($45.31M) | ($43.27M) | ($41.03M) | ($39.41M) |
| Net Margin %(computed) | — | -104.74% | -170.51% | -232.44% | -317.44% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.89 | $-2.37 | $-3.48 | $-3.78 | $-1.35 |
| Wtd Avg Shares | 47.23M | 15.42M | 12.36M | 10.73M | 29.65M |
| EBITDA | ($89.20M) | ($48.99M) | ($49.78M) | ($49.27M) | ($45.42M) |
| EBITDA Margin %(computed) | — | -113.25% | -196.17% | -279.12% | -365.86% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Silence Therapeutics plc data
About Silence Therapeutics plc (SLN) Income Statement
Silence Therapeutics plc (SLN) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SLN reported revenue of $0.00B, gross profit of $0.00B (gross margin 61.54%), and net income of ($0.09B) — a net profit margin of -15851.88%.
Frequently asked questions
SLN · 4 questionsSilence Therapeutics plc (SLN) reported revenue of $0.00B for 2025, down 98.7% year-over-year.
SLN revenueSLN salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08